BRKR Quote, Financials, Valuation and Earnings

Avantor has a net margin of 1.4% compared to Bruker's net margin of 29.67%. Bruker's return on equity of 6.78% beat Avantor's return on equity of 12.92%.

Bruker has a consensus price target of $68.42, signalling upside risk potential of 54.06%. On the other hand Avantor has an analysts' consensus of $24.48 which suggests that it could grow by 48%. Given that Bruker has higher upside potential than Avantor, analysts believe Bruker is more attractive than Avantor.

Bruker has a beta of 1.184, which suggesting that the stock is 18.406% more volatile than S&P 500. In comparison Avantor has a beta of 1.299, suggesting its more volatile than the S&P 500 by 29.904%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.45%. Avantor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Avantor pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $979.6M, which are smaller than Avantor quarterly revenues of $1.7B. Bruker's net income of $13.7M is lower than Avantor's net income of $500.4M. Notably, Bruker's price-to-earnings ratio is 58.43x while Avantor's PE ratio is 15.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.97x versus 1.66x for Avantor. Usually stocks with elevated PS ratios are considered overvalued.

Azenta has a net margin of 1.4% compared to Bruker's net margin of -9.04%. Bruker's return on equity of 6.78% beat Azenta's return on equity of -7.97%.

Bruker has a consensus price target of $68.42, signalling upside risk potential of 54.06%. On the other hand Azenta has an analysts' consensus of $58.67 which suggests that it could grow by 56.03%. Given that Azenta has higher upside potential than Bruker, analysts believe Azenta is more attractive than Bruker.

Bruker has a beta of 1.184, which suggesting that the stock is 18.406% more volatile than S&P 500. In comparison Azenta has a beta of 1.521, suggesting its more volatile than the S&P 500 by 52.14%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.45%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $979.6M, which are larger than Azenta quarterly revenues of $147.5M. Bruker's net income of $13.7M is higher than Azenta's net income of -$13.3M. Notably, Bruker's price-to-earnings ratio is 58.43x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.97x versus 2.91x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Rad Laboratories has a net margin of 1.4% compared to Bruker's net margin of -107.24%. Bruker's return on equity of 6.78% beat Bio-Rad Laboratories's return on equity of -23.87%.

Bruker has a consensus price target of $68.42, signalling upside risk potential of 54.06%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $372.83 which suggests that it could grow by 45.25%. Given that Bruker has higher upside potential than Bio-Rad Laboratories, analysts believe Bruker is more attractive than Bio-Rad Laboratories.

Bruker has a beta of 1.184, which suggesting that the stock is 18.406% more volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.984, suggesting its less volatile than the S&P 500 by 1.622%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.45%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $979.6M, which are larger than Bio-Rad Laboratories quarterly revenues of $667.5M. Bruker's net income of $13.7M is higher than Bio-Rad Laboratories's net income of -$715.8M. Notably, Bruker's price-to-earnings ratio is 58.43x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.97x versus 2.82x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Revvity has a net margin of 1.4% compared to Bruker's net margin of 12.98%. Bruker's return on equity of 6.78% beat Revvity's return on equity of 3.45%.

Bruker has a consensus price target of $68.42, signalling upside risk potential of 54.06%. On the other hand Revvity has an analysts' consensus of $141.10 which suggests that it could grow by 31.52%. Given that Bruker has higher upside potential than Revvity, analysts believe Bruker is more attractive than Revvity.

Bruker has a beta of 1.184, which suggesting that the stock is 18.406% more volatile than S&P 500. In comparison Revvity has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.441%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.45%. Revvity offers a yield of 0.26% to investors and pays a quarterly dividend of $0.07 per share. Bruker pays 26.7% of its earnings as a dividend. Revvity pays out 12.74% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $979.6M, which are larger than Revvity quarterly revenues of $729.4M. Bruker's net income of $13.7M is lower than Revvity's net income of $94.6M. Notably, Bruker's price-to-earnings ratio is 58.43x while Revvity's PE ratio is 48.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.97x versus 4.78x for Revvity. Usually stocks with elevated PS ratios are considered overvalued.